Skip to main content

ESTUDIO DE REGULADORES DE LA PROGRESION DEL CANCER DE PROSTATA EN LA INTERFASE DE METABOLISMO Y SEÑALIZACION CELULAR

PID2019-108787RB-I00

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Call year 2019
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre ASOCIACION CENTRO DE INVESTIGACION COOP EN BIOCIENCIAS CIC BIOGUNE

Resultados relacionados

Resultados totales (Incluyendo duplicados): 7
Encontrada(s) 1 página(s)

Investigo. Repositorio Institucional de la Universidade de Vigo
Publication Artículo científico (JournalArticle)

Machine learning‐assisted high‐throughput SERS classification of cell secretomes

  • Plou, Javier
  • Valera, Pablo S.
  • García, Isabel
  • Vila Liarte, David
  • Renero Lecuna, Carlos
  • Ruiz Cabello, Jesús
  • Carracedo, Arkaitz
  • Liz Marzán, Luis Manuel
During the response to different stress conditions, damaged cells react in multiple ways, including the release of a diverse cocktail of metabolites. Moreover, secretomes from dying cells can contribute to the effectiveness of anticancer therapies and can be exploited as predictive biomarkers. The nature of the stress and the resulting intracellular responses are key determinants of the secretome composition, but monitoring such processes remains technically arduous. Hence, there is growing interest in developing tools for noninvasive secretome screening. In this regard, it has been previously shown that the relative concentrations of relevant metabolites can be traced by surface-enhanced Raman scattering (SERS), thereby allowing label-free biofluid interrogation. However, conventional SERS approaches are insufficient to tackle the requirements imposed by high-throughput modalities, namely fast data acquisition and automatized analysis. Therefore, machine learning methods were implemented to identify cell secretome variations while extracting standard features for cell death classification. To this end, ad hoc microfluidic chips were devised, to readily conduct SERS measurements through a prototype relying on capillary pumps made of filter paper, which eventually would function as the SERS substrates. The developed strategy may pave the way toward a faster implementation of SERS into cell secretome classification, which can be extended even to laboratories lacking highly specialized facilities., Universidade de Vigo/CISUG, Agencia Estatal de Investigación | Ref. PID2019-108787RB-I00
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Genomic and Functional Regulation of TRIB1 Contributes to Prostate Cancer Pathogenesis

  • Shahrouzi, Parastoo
  • Astobiza, Ianire
  • Cortázar, Ana R.
  • Torrano, Verónica
  • Macchia, Alice
  • Flores, Juana María
  • Niespolo, Chiara
  • Mendizábal, Isabel
  • Caloto, Rubén
  • Ercilla, Amaia
  • Camacho, Laura
  • Arreal, Leire
  • Bizkarguenaga, Maider
  • Martínez-Chantar, María Luz
  • Bustelo, Xosé R.
  • Berra, Edurne
  • Kiss-Toth, Endre
  • Velasco, Guillermo
  • Zabala-Letona, Amaia
  • Carracedo, Arkaitz
© 2020 by the authors., Prostate cancer is the most frequent malignancy in European men and the second worldwide. One of the major oncogenic events in this disease includes amplification of the transcription factor cMYC. Amplification of this oncogene in chromosome 8q24 occurs concomitantly with the copy number increase in a subset of neighboring genes and regulatory elements, but their contribution to disease pathogenesis is poorly understood. Here we show that TRIB1 is among the most robustly upregulated coding genes within the 8q24 amplicon in prostate cancer. Moreover, we demonstrate that TRIB1 amplification and overexpression are frequent in this tumor type. Importantly, we find that, parallel to its amplification, TRIB1 transcription is controlled by cMYC. Mouse modeling and functional analysis revealed that aberrant TRIB1 expression is causal to prostate cancer pathogenesis. In sum, we provide unprecedented evidence for the regulation and function of TRIB1 in prostate cancer., We are grateful to the Carracedo lab for valuable input, to Ana M. Aransay and F. Elortza for technical advice. P.S. was funded by the European Training Networks Project (H2020-MSCA-ITN-308 2016 721532). V.T. is funded by Fundación Vasca de Innovación e Investigación Sanitarias, BIOEF (BIO15/CA/052), the AECC J.P. Bizkaia, the Basque Department of Health (2016111109) and the MICINN RTI2018-097267-B-I00. A. Macchia was funded by a FPI predoctoral fellowship from MICINN (PRE2018-083607). EB is funded by the MICINN (BFU2016-76872-R (FEDER/EU), PID2019-108112RB-I00, Severo Ochoa Excellence Accreditation SEV-2016-0644 and Excellence Networks SAF2017-90794-REDT). The work of A. Carracedo is supported by the Basque Department of Industry, Tourism and Trade (Elkartek), the department of education (IKERTALDE IT1106-16) and health (RIS3), the BBVA foundation and the MICINN (SAF2016-79381-R (FEDER/EU; PID2019-108787RB-I00) Severo Ochoa Excellence Accreditation SEV-2016-0644 and Excellence Networks SAF2016-81975-REDT and RED2018-102769-T), European Training Networks Project (H2020-MSCA-ITN-308 2016 721532), the AECC (IDEAS175CARR, GCTRA18006CARR), La Caixa Foundation (ID 100010434), under the agreement LCF/PR/HR17/ and the European Research Council (Starting Grant 336343, Consolidator Grant 819242). CIBERONC was co-funded with FEDER funds and funded by ISCIII.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Stromal oncostatin M cytokine promotes breast cancer progression by reprogramming the tumor microenvironment

  • Araujo, Angela M.
  • Abaurrea, Andrea
  • Azcoaga, Peio
  • López-Velazco, Joanna I.
  • Manzano, Sara
  • Rodríguez, Javier
  • Rezola, Ricardo
  • Egia-Mendikute, Leire
  • Valdés-Mora, Fátima
  • Flores, Juana M.
  • Jenkins, Liam
  • Pulido, Laura
  • Osorio-Querejeta, Iñaki
  • Fernández-Nogueira, Patricia
  • Ferrari, Nicola
  • Viera, Cristina
  • Martín-Martín, Natalia
  • Tzankov, Alexandar
  • Eppenberger-Castori, Serenella
  • Álvarez-López, Isabel
  • Urruticoechea, Ander
  • Bragado, Paloma
  • Coleman, Nicholas
  • Palazón, Asís
  • Carracedo, Arkaitz
  • Gallego-Ortega, David
  • Calvo, Fernando
  • Isacke, Clare M.
  • Caffarel, María M.
  • Lawrie, Charles H.
The tumor microenvironment (TME) is reprogrammed by cancer cells and participates in all stages of tumor progression. The contribution of stromal cells to the reprogramming of the TME is not well understood. Here, we provide evidence of the role of the cytokine oncostatin M (OSM) as central node for multicellular interactions between immune and nonimmune stromal cells and the epithelial cancer cell compartment. OSM receptor (OSMR) deletion in a multistage breast cancer model halted tumor progression. We ascribed causality to the stromal function of the OSM axis by demonstrating reduced tumor burden of syngeneic tumors implanted in mice lacking OSMR. Single-cell and bioinformatic analysis of murine and human breast tumors revealed that OSM expression was restricted to myeloid cells, whereas OSMR was detected predominantly in fibroblasts and, to a lower extent, cancer cells. Myeloid-derived OSM reprogrammed fibroblasts to a more contractile and tumorigenic phenotype and elicited the secretion of VEGF and proinflammatory chemokines CXCL1 and CXCL16, leading to increased myeloid cell recruitment. Collectively, our data support the notion that the stromal OSM/OSMR axis reprograms the immune and nonimmune microenvironment and plays a key role in breast cancer progression., This work was funded by Spanish Ministry of Science and Innovation - ISCIII (PI15/00623, PI18/00458, PI21/01208, CP18/00076, and FI19/00193); European Regional Development (FEDER) funds; Basque Department of Health (2017111011); Fundación SEOM (Beca SEOM-Font Vella); Fundación Gangoiti; and Ikerbasque Basque Research Foundation. The group also received funds from the breast cancer patient’s charity Katxalin and from Roche Farma S.A. AMA and AA are funded by Basque Government Doctoral Training Grants. JILV is funded by an AECC PhD Fellowship. FVM is supported by the Career Development Fellowship from the Cancer Institute New South Wales (2019/CDF002). AP’s research is funded by the European Research Council (ERC, ERC-2018-StG 804236-NEXTGEN-IO), and by the Spanish Ministry of Science and Innovation (PID2019-107956RA-I00 and RYC2018-024183-I). AC’s research is supported by the Basque Department of Industry, Tourism and Trade (Elkartek); the MICINN (PID2019-108787RB-I00 [FEDER/EU]; Excellence Network (SAF2016-81975-REDT); European Training Networks Project (H2020-MSCA-ITN-308 2016 721532); the AECC (GCTRA18006CARR), Vencer el Cáncer Foundation; La Caixa Foundation (ID 100010434), under the agreement LCF/PR/HR17/; and the ERC (Consolidator Grant 819242). CIBERONC was cofunded with FEDER funds and funded by ISCIII. DGO is supported by a Cancer Council NSW project grant (RG18-03) and the National Breast Cancer Foundation Elaine Henry Fellowship (IIRS-21-096). FC is funded by Institute of Cancer Research, Spanish Ministry of Science and Innovation (RYC-2016-20352 and RTI2018-096778-A-I00); Asociacion Española Contra el Cancer (LAB-AECC, LABAE19044CALV); and BBVA Leonardo Awards (IN[19]_BBM_BAS_0076).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

CiberAMP: an R package to identify differential mRNA expression linked to somatic copy number variations in cancer datasets

  • Caloto, Rubén
  • Lorenzo-Martín, L. Francisco
  • Quesada, Víctor
  • Carracedo, Arkaitz
  • Bustelo, Xosé R.
Somatic copy number variations (SCNVs) are genetic alterations frequently found in cancer cells. These genetic alterations can lead to concomitant perturbations in the expression of the genes included in them and, as a result, promote a selective advantage to cancer cells. However, this is not always the case. Due to this, it is important to develop in silico tools to facilitate the accurate identification and functional cataloging of gene expression changes associated with SCNVs from pan-cancer data. Here, we present a new R-coded tool, designated as CiberAMP, which utilizes genomic and transcriptomic data contained in the Cancer Genome Atlas (TCGA) to identify such events. It also includes information on the genomic context in which such SCNVs take place. By doing so, CiberAMP provides clues about the potential functional relevance of each of the SCNV-associated gene expression changes found in the interrogated tumor samples. The main features and advantages of this new algorithm are illustrated using glioblastoma data from the TCGA database, X.R.B.’s project leading to these results has received funding from the RTI2018-096481-B-100 grant cofounded by MCIN/AEI/10.13039/501100011033 plus the European Research Development Fund “A way of making Europe” of the European Union, the Spanish Association against Cancer (GC16173472GARC), the Castilla-León autonomous government (CSI252P18, CSI145P20, and CLC2017-01), and “la Caixa” Banking Foundation (HR20-00164). X.R.B.’s institution is supported by the Programa de Apoyo a Planes Estratégicos de Investigación de Estructuras de Investigación de Excelencia of the Castilla-León autonomous government (CLC-2017-01). R.C. has been supported by a predoctoral contract from the Spanish Ministry of Science and Innovation (BES-2016-0077909) and the CLC-2017-01 grant. L.F.L.-M.’s position has been mostly supported by funding from the Spanish Ministry of Education, Culture and Sports (FPU13/02923) and, subsequently, by the CLC-2017-01 grant. A.C. is supported by the MICINN (PID2019-108787RB-I00) and the European Research Council (Consolidator Grant 819242).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

METTL1 promotes tumorigenesis through tRNA-derived fragment biogenesis in prostate cancer

  • García-Vílchez, Raquel
  • Añazco-Guenkova, Ana M.
  • Dietmann, Sabine
  • López, Judith
  • Morón-Calvente, Virginia
  • D'Ambrosi, Silvia
  • Nombela, Paz
  • Zamacola, Kepa
  • Mendizábal, Isabel
  • García-Longarte, Saioa
  • Zabala-Letona, Amaia
  • Astobiza, Ianire
  • Fernández, Sonia
  • Paniagua, Alejandro
  • Miguel-López, Borja
  • Marchand, Virginie
  • Alonso-López, Diego
  • Merkel, Angelika
  • García-Tuñón, Ignacio
  • Ugalde-Olano, Aitziber
  • Loizaga-Iriarte, Ana
  • Lacasa-Viscasillas, Isabel
  • Unda, Miguel
  • Azkargorta, Mikel
  • Elortza, Félix
  • Bárcena, Laura
  • Gonzalez-Lopez, Monika
  • Aransay, Ana M.
  • Di Domenico, Tomás
  • Sánchez-Martín, Manuel A.
  • De Las Rivas, Javier
  • Guil, Sònia
  • Motorin, Yuri
  • Helm, Mark
  • Pandolfi, Pier Paolo
  • Carracedo, Arkaitz
  • Blanco, Sandra
Newly growing evidence highlights the essential role that epitranscriptomic marks play in the development of many cancers; however, little is known about the role and implications of altered epitranscriptome deposition in prostate cancer. Here, we show that the transfer RNA N7-methylguanosine (m7G) transferase METTL1 is highly expressed in primary and advanced prostate tumours. Mechanistically, we find that METTL1 depletion causes the loss of m7G tRNA methylation and promotes the biogenesis of a novel class of small non-coding RNAs derived from 5'tRNA fragments. 5'tRNA-derived small RNAs steer translation control to favour the synthesis of key regulators of tumour growth suppression, interferon pathway, and immune effectors. Knockdown of Mettl1 in prostate cancer preclinical models increases intratumoural infiltration of pro-inflammatory immune cells and enhances responses to immunotherapy. Collectively, our findings reveal a therapeutically actionable role of METTL1-directed m7G tRNA methylation in cancer cell translation control and tumour biology., This work was funded by the Spanish Ministry of Science and Innovation MICINN/AEI/1013039/501100011033 and by “ERDF A way of making Europe”, by the “European Union” (SAF2016-78667-R and PID2019-111692RB-I00), MINECO (RYC-2014-16550), AECC (LABAE19040BLAN), Proteored-ISCIII, and Consejería de Educación de la Junta de Castilla y León (CSI264P20). R.G-V. was supported by MICINN/AEI/1013039/501100011033 and by “ESF Investing in your future” (BES-2017-080530). A.M.A-G. was supported by the USAL-Santander PhD fellowship. J.L-L. was supported by the AECC (PRDSA19002LÓPE) and MIU(FPU19/01190). B.M.L. was supported by Junta de Castilla y León ‐ Fondo Social Europeo (ESF). I.M. was supported by the Cris contra el cáncer grant PR_TPD_2020-19. The work of A. Carracedo is supported by the MICINN (PID2019-108787RB-I00 (FEDER/EU); Excellence Networks RED2018-102769-T), the AECC (GCTRA18006CARR), La Caixa Foundation (ID 100010434), under the agreement LCF/PR/HR17/ and the European Research Council (Consolidator Grant 819242). CIBERONC was co-funded by FEDER funds and ISCIII. The Instituto de Biología Molecular y Celular del Cancer is supported by the Programa de Apoyo a Planes Estratégicos de Investigación de Estructuras de Investigación de Excelencia co-financed by the Castilla–León autonomous government and the European Regional Development Fund (CLC–2017–01)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

SERS analysis of cancer cell-secreted purines reveals a unique paracrine crosstalk in MTAP-deficient tumors

  • Valera, Pablo S.
  • Plou, Javier
  • García, Isabel
  • Astobiza, Ianire
  • Viera, Cristina
  • Aransay, Ana M.
  • Martin, José E.
  • Sasselli, Ivan R.
  • Carracedo, Arkaitz
  • Liz-Marzán, Luis Manuel
RNA Sequencing source data isaccessible at the Gene Expression Omnibus (reference: GSE249082) (46)., [Significance] This research unveils a unique paracrine crosstalk in the tumor microenvironment (TME) involving cancer cells with methylthioadenosine phosphorylase (MTAP) deletions, a common trait linked to poor prognosis. Using surface-enhanced Raman Scattering (SERS), we discovered that these cells secrete 5′-methylthioadenosine (MTA), which can be further metabolized by fibroblasts, leading to molecular changes consistent with cancer aggressiveness and affecting macrophage polarization. Our study not only highlights the potential of SERS for exploring secreted signatures in cancer research but also offers valuable insight to guide more targeted experiments toward deciphering the role of such secreted metabolites in the TME, which could inform future therapeutic strategies., The tumor microenvironment (TME) is a dynamic pseudoorgan that shapes the development and progression of cancers. It is a complex ecosystem shaped by interactions between tumor and stromal cells. Although the traditional focus has been on the paracrine communication mediated by protein messengers, recent attention has turned to the metabolic secretome in tumors. Metabolic enzymes, together with exchanged substrates and products, have emerged as potential biomarkers and therapeutic targets. However, traditional techniques for profiling secreted metabolites in complex cellular contexts are limited. Surface-enhanced Raman scattering (SERS) has emerged as a promising alternative due to its nontargeted nature and simplicity of operation. Although SERS has demonstrated its potential for detecting metabolites in biological settings, its application in deciphering metabolic interactions within multicellular systems like the TME remains underexplored. In this study, we introduce a SERS-based strategy to investigate the secreted purine metabolites of tumor cells lacking methylthioadenosine phosphorylase (MTAP), a common genetic event associated with poor prognosis in various cancers. Our SERS analysis reveals that MTAP-deficient cancer cells selectively produce methylthioadenosine (MTA), which is taken up and metabolized by fibroblasts. Fibroblasts exposed to MTA exhibit: i) molecular reprogramming compatible with cancer aggressiveness, ii) a significant production of purine derivatives that could be readily recycled by cancer cells, and iii) the capacity to secrete purine derivatives that induce macrophage polarization. Our study supports the potential of SERS for cancer metabolism research and reveals an unprecedented paracrine crosstalk that explains TME reprogramming in MTAP-deleted cancers., L.M.L.-M. acknowledges funding from the European Research Council (ERC AdG 787510, 4DbioSERS). A.C. was funded by Ministerio de Ciencia e Innovación (MICINN) [PID2019-108787RB-I00 Fondo Europeo de Desarrollo Regional (FEDER/EU)] and the European Research Council (ERC Consolidator Grant 819242)., Peer reviewed
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

METTL1 promotes tumorigenesis through tRNA-derived fragment biogenesis in prostate cancer

  • García-Vílchez, Raquel
  • Añazco-Guenkova, Ana M.
  • Dietmann, Sabine
  • López, Judith
  • Morón-Calvente, Virginia
  • D'Ambrosi, Silvia
  • Nombela, Paz
  • Zamacola, Kepa
  • Mendizabal, Isabel
  • García-Longarte, Saioa
  • Zabala-Letona, Amaia
  • Astobiza, Ianire|||0000-0002-7142-7066
  • Fernández, Sonia
  • Paniagua, Alejandro|||0000-0002-7794-8321
  • Miguel-López, Borja
  • Marchand, Virginie
  • Alonso-López, Diego
  • Merkel, Angelika|||0000-0001-5164-6803
  • García-Tuñón, Ignacio
  • Ugalde-Olano, Aitziber
  • Loizaga-Iriarte, Ana
  • Lacasa-Viscasillas, Isabel
  • Unda, Miguel
  • Azkargorta, Mikel
  • Elortza, Felix|||0000-0001-8839-5438
  • Barcena, Laura
  • Gonzalez-Lopez, Monika
  • Aransay, Ana M.|||0000-0002-8271-612X
  • Di Domenico, Tomás
  • Sánchez-Martín, Manuel A.|||0000-0001-8370-1336
  • De Las Rivas, Javier
  • Guil, Sonia|||0000-0002-2257-3331
  • Motorin, Yuri
  • Helm, Mark|||0000-0002-0154-0928
  • Pandolfi, Pier Paolo
  • Carracedo, Arkaitz|||0000-0001-5957-1260
  • Blanco, Sandra
Newly growing evidence highlights the essential role that epitranscriptomic marks play in the development of many cancers; however, little is known about the role and implications of altered epitranscriptome deposition in prostate cancer. Here, we show that the transfer RNA N7-methylguanosine (m7G) transferase METTL1 is highly expressed in primary and advanced prostate tumours. Mechanistically, we find that METTL1 depletion causes the loss of m7G tRNA methylation and promotes the biogenesis of a novel class of small non-coding RNAs derived from 5'tRNA fragments. 5'tRNA-derived small RNAs steer translation control to favour the synthesis of key regulators of tumour growth suppression, interferon pathway, and immune effectors. Knockdown of Mettl1 in prostate cancer preclinical models increases intratumoural infiltration of pro-inflammatory immune cells and enhances responses to immunotherapy. Collectively, our findings reveal a therapeutically actionable role of METTL1-directed m7G tRNA methylation in cancer cell translation control and tumour biology.